View:
Download DOC
Download PDF
Download XLS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported):
July 23, 2015


CHEMED CORPORATION
(Exact name of registrant as specified in its charter)

Delaware

1-8351

31-0791746

(State or other

jurisdiction of

incorporation)

(Commission File Number)

(I.R.S. Employer

Identification

Number)


Suite 2600, 255 East 5th Street, Cincinnati, OH 45202

(Address of principal executive offices)           (Zip Code)


Registrant’s telephone number, including area code:
(513) 762-6690


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

⃞           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Page 1 of 2

Item 2.02 Results of Operations and Financial Condition

On July 23, 2015 Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2015.  A copy of the release is furnished herewith as Exhibit 99.        


Item 9.01 Financial Statements and Exhibits

  d) Exhibit
(99) Registrant’s press release dated July 23, 2015




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



CHEMED CORPORATION

 

 

Dated:

July 23, 2015

By:

/s/  Arthur V. Tucker Jr.

 

Arthur V. Tucker, Jr.

 

Vice President and Controller


Page 2 of 2

Exhibit 99

Chemed Reports Second-Quarter 2015 Results

•  Increases 2015 Earnings Guidance

CINCINNATI--(BUSINESS WIRE)--July 23, 2015--Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest provider of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2015, versus the comparable prior-year period, as follows:

Consolidated operating results:

  • Revenue increased 6.0% to $382 million
  • GAAP Diluted EPS increased 14.0% to $1.55
  • Adjusted Diluted EPS increased 14.0% to $1.71

VITAS segment operating results:

  • Net Patient Revenue of $276 million, an increase of 4.7%
  • Average Daily Census (ADC) of 15,283, an increase of 5.1%
  • Admissions of 16,683, an increase of 5.8%
  • Net Income, including litigation costs, of $21.8 million, an increase of 4.3%
  • Adjusted EBITDA of $39.8 million, an increase of 6.3%
  • Adjusted EBITDA margin of 14.4%, an increase of 21 basis points

Roto-Rooter segment operating results:

  • Revenue of $105 million, an increase of 9.7%
  • Net Income of $12.2 million, an increase of 13.4%
  • Adjusted EBITDA of $22.0 million, an increase of 15.5%
  • Adjusted EBITDA margin of 20.9%, an increase of 105 basis points

VITAS

Net revenue for VITAS was $276 million in the second quarter of 2015, which is an increase of $12.4 million, or 4.7%, when compared to the prior-year period. This revenue increase is comprised of an average Medicare reimbursement rate increase of approximately 1.4%, a 5.1% increase in average daily census, offset by level of care and geographic mix shift, when compared to the prior year.

In the second quarter of 2015, VITAS did not record any adjustments in estimated Medicare Cap billing limitations. This compares to $0.1 million of Medicare Cap billing limitations recorded in the second quarter of 2014.

At June 30, 2015, VITAS had 34 Medicare provider numbers, none of which has an estimated 2015 Medicare Cap billing limitation.

Of VITAS’ 34 unique Medicare provider numbers, 32 provider numbers have a Medicare Cap cushion of 10% or greater for the 2015 Medicare Cap period, one provider number has a cap cushion between 5% and 10% and one provider number has a cap cushion between 0% and 5%. VITAS generated an aggregate cap cushion of $297 million during the trailing twelve-month period.

Average revenue per patient per day in the quarter, excluding the impact of Medicare Cap, was $198.79, which is 0.5% below the prior-year period. Routine home care reimbursement and high acuity care averaged $164.07 and $698.96, respectively. During the quarter, high acuity days of care were 6.5% of total days of care, 40 basis points less than the prior-year quarter.

The second quarter of 2015 gross margin, excluding the impact of Medicare Cap, was 21.9%, which is 14 basis points below the second quarter of 2014.

Selling, general and administrative expense was $22.2 million in the second quarter of 2015, which is an increase of 5.9% when compared to the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $39.8 million in the quarter, an increase of 5.9% over the prior-year period. Adjusted EBITDA margin, excluding the impact from Medicare Cap, was 14.4% in the quarter which is 17 basis points favorable to the prior-year period.

Roto-Rooter

Roto-Rooter generated sales of $105 million for the second quarter of 2015, an increase of $9.3 million, or 9.7%, over the prior-year quarter. Water restoration accounted for the majority of this revenue growth, with water and flood remediation services increasing $5.8 million in the quarter.

Roto-Rooter’s gross margin in the quarter was 48.0%, a 119 basis point improvement when compared to the second quarter of 2014. Adjusted EBITDA in the second quarter of 2015 totaled $22.0 million, an increase of 15.5%, and the Adjusted EBITDA margin was 20.9% in the quarter, 105 basis points higher than the prior year.

Chemed Consolidated

As of June 30, 2015, Chemed had total cash and cash equivalents of $32.7 million and debt of $160 million.

In June 2014 Chemed entered into a five-year Amended and Restated Credit Agreement that consisted of a $100 million amortizable term loan and a $350 million revolving credit facility. The interest rate on this facility has a floating rate that is currently LIBOR plus 112.5 basis points. At June 30, 2015, the Company had approximately $248 million of undrawn borrowing capacity under this credit agreement.

Capital expenditures through June 30, 2015, aggregated $18.8 million and compares to depreciation and amortization during the same period of $17.3 million.

The Company repurchased $29.8 million of Chemed stock during the quarter. This equates to 250,000 shares of Chemed stock repurchased at an average cost of $119.05 Chemed currently has $82.0 million of authorization remaining under this share repurchase plan.

Guidance for 2015

Full-year 2015 revenue growth for VITAS, prior to Medicare Cap, is estimated to be in the range of 4% to 5%. Admissions in 2015 are estimated to increase 4% to 5% and full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 14% to 15%. Medicare Cap billing limitations for calendar year 2015 are estimated to be $2.8 million.

Roto-Rooter is forecasted to achieve full-year 2015 revenue growth of 5% to 6%. This revenue estimate is based upon continued expansion in water restoration services coupled with increased job pricing of approximately 1%. Adjusted EBITDA margin for 2015 is estimated in the range of 19.5% to 20.0%.

Management estimates that full-year 2015 adjusted earnings per diluted share, which excludes non-cash expense for stock options, costs related to litigation, and other discrete items, will be in the range of $6.60 to $6.75. This compares to Chemed’s 2014 reported adjusted earnings per diluted share of $6.07.

Conference Call

Chemed will host a conference call and webcast at 10 a.m., ET, on Friday, July 24, 2015, to discuss the Company's quarterly results and to provide an update on its business. The dial-in number for the conference call is (866) 510-0712 for U.S. and Canadian participants and (617) 597-5380 for international participants. The participant passcode is 60045204. A live webcast of the call can be accessed on Chemed's website at www.chemed.com by clicking on Investor Relations Home.

A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (888) 286-8010 for U.S. and Canadian callers and (617) 801-6888 for international callers and will be available for one week following the live call. The replay pass code is 19930482. An archived webcast will also be available at www.chemed.com.

Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to over 15,000 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing and drain service through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

Forward-Looking Statements

Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.

These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed’s dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF INCOME
(in thousands, except per share data)(unaudited)
                   
 
Three Months Ended June 30, Six Months Ended June 30,
2015 2014 2015 2014
Service revenues and sales $ 381,921   $ 360,182   $ 758,573   $ 718,482  
Cost of services provided and goods sold 270,663 257,007 539,548 514,826
Selling, general and administrative expenses (aa) 57,994 53,649 116,582 109,320
Depreciation 8,082 7,272 16,114 14,421
Amortization   582     735     1,158     1,744  
Total costs and expenses   337,321     318,663     673,402     640,311  
Income from operations 44,600 41,519 85,171 78,171
Interest expense (969 ) (2,429 ) (1,938 ) (6,244 )
Other income--net (bb)   536     756     1,099     1,572  
Income before income taxes 44,167 39,846 84,332 73,499
Income taxes   (17,192 )   (15,483 )   (32,820 )   (28,562 )
Net income $ 26,975   $ 24,363   $ 51,512   $ 44,937  
 
 
Earnings Per Share
Net income $ 1.60   $ 1.41   $ 3.05   $ 2.59  
Average number of shares outstanding   16,880     17,236     16,872     17,374  
 
Diluted Earnings Per Share
Net income $ 1.55   $ 1.36   $ 2.96   $ 2.48  
Average number of shares outstanding   17,419     17,880     17,419     18,097  
 
 
 
                       
(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):
 
Three Months Ended June 30, Six Months Ended June 30,
2015 2014 2015 2014

SG&A expenses before long-term incentive compensation and the impact of market gains related to deferred compensation plans

$ 56,039 $ 52,386 $ 112,743 $ 106,522

Market value gains related to deferred compensation plans (cc)

498 650 1,448 1,812
Long-term incentive compensation   1,457     613     2,391     986  
Total SG&A expenses $ 57,994   $ 53,649   $ 116,582   $ 109,320  
 
(bb) Other income--net comprises (in thousands):
 
Three Months Ended June 30, Six Months Ended June 30,
2015 2014 2015 2014

Market value gains related to deferred compensation plans

$ 498 $ 650 $ 1,448 $ 1,812
Interest income 86 58 130 8
Loss on disposal of property and equipment (63 ) (48 ) (15 ) (326 )
Other   15     96     (464 )   78  
Total other income--net $ 536   $ 756   $ 1,099   $ 1,572  
 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEET
(in thousands, except per share data)(unaudited)
                   
 
June 30,
2015 2014
Assets
Current assets
Cash and cash equivalents $ 32,705 $ 27,913
Accounts receivable less allowances 119,116 92,152
Inventories 6,250 6,856
Current deferred income taxes 16,432 13,459
Prepaid income taxes 3,474 4,001
Prepaid expenses   12,069     21,119  
Total current assets 190,046 165,500
Investments of deferred compensation plans held in trust 51,940 47,314
Properties and equipment, at cost less accumulated depreciation 107,556 97,206
Identifiable intangible assets less accumulated amortization 55,979 56,288
Goodwill 472,546 466,867
Other assets   7,216     8,420  
Total Assets $ 885,283   $ 841,595  
 
Liabilities
Current liabilities
Accounts payable $ 39,327 $ 35,013
Current portion of long-term debt 7,500 5,000
Income taxes 20 6,029
Accrued insurance 42,589 40,164
Accrued compensation 48,909 42,527
Accrued legal 1,815 7,429
Other current liabilities   21,752     20,511  
Total current liabilities 161,912 156,673
Deferred income taxes 28,280 27,270
Long-term debt 152,500 155,000
Deferred compensation liabilities 52,051 46,917
Other liabilities   12,742     11,251  
Total Liabilities   407,485     397,111  
 
Stockholders' Equity
Capital stock 33,620 32,980
Paid-in capital 562,654 511,794
Retained earnings 815,229 724,295
Treasury stock, at cost (936,056 ) (826,802 )
Deferred compensation payable in Company stock   2,351     2,217  
Total Stockholders' Equity   477,798     444,484  
Total Liabilities and Stockholders' Equity $ 885,283   $ 841,595  
 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)(unaudited)
                     
 
Six Months Ended June 30,
2015 2014
Cash Flows from Operating Activities
Net income $ 51,512 $ 44,937

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 17,272 16,165
Provision for uncollectible accounts receivable 7,734 6,449
Stock option expense 2,787 2,453
Provision for deferred income taxes (2,783 ) 6,180
Noncash long-term incentive compensation 2,391 986
Amortization of debt issuance costs 262 564
Amortization of discount on convertible notes - 3,392

Changes in operating assets and liabilities, excluding amounts acquired in business combinations:

Increase in accounts receivable (2,182 ) (6,782 )
Increase in inventories (78 ) (153 )
Increase in prepaid expenses (507 ) (3,301 )

Decrease in accounts payable and other current liabilities

(1,314 ) (33,584 )
Increase/(decrease) in income taxes (2,384 ) 7,224
Increase in other assets (2,229 ) (2,748 )
Increase in other liabilities 2,966 4,644
Excess tax benefit on share-based compensation (3,998 ) (1,866 )
Other sources   189     553  
Net cash provided by operating activities   69,638     45,113  
Cash Flows from Investing Activities
Capital expenditures (18,846 ) (19,454 )
Business combinations, net of cash acquired (6,614 ) (250 )
Other sources   395     192  
Net cash used by investing activities   (25,065 )   (19,512 )
Cash Flows from Financing Activities
Proceeds from revolving line of credit 103,200 245,500
Payments on revolving line of credit (88,200 ) (185,500 )
Payments on other long-term debt (2,500 ) (186,956 )
Proceeds from other long-term debt - 100,000
Purchases of treasury stock (29,762 ) (58,493 )
Proceeds from exercise of stock options 8,044 16,092
Dividends paid (7,459 ) (6,757 )
Decrease in cash overdrafts payable (6,791 ) (479 )
Capital stock surrendered to pay taxes on stock-based compensation (5,876 ) (3,543 )
Excess tax benefit on share-based compensation 3,998 1,866
Debt issuances costs - (939 )
Retirement of warrants - (2,645 )
Other uses   (654 )   (252 )
Net cash used by financing activities   (26,000 )   (82,106 )
Increase/(Decrease) in Cash and Cash Equivalents 18,573 (56,505 )
Cash and cash equivalents at beginning of year   14,132     84,418  
Cash and cash equivalents at end of period $ 32,705   $ 27,913  
 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2015 AND 2014
(in thousands)(unaudited)
               
Chemed
VITAS Roto-Rooter Corporate Consolidated
2015
Service revenues and sales $ 276,460   $ 105,461   $ -   $ 381,921  
Cost of services provided and goods sold 215,778 54,885 - 270,663
Selling, general and administrative expenses (a) 22,237 28,241 7,516 57,994
Depreciation 4,724 3,205 153 8,082
Amortization   171     128     283     582  
Total costs and expenses   242,910     86,459     7,952     337,321  
Income/(loss) from operations 33,550 19,002 (7,952 ) 44,600
Interest expense (a) (53 ) (98 ) (818 ) (969 )
Intercompany interest income/(expense) 1,755 805 (2,560 ) -
Other income/(expense)—net   49     (12 )   499     536  
Income/(loss) before income taxes 35,301 19,697 (10,831 ) 44,167
Income taxes (a)   (13,501 )   (7,544 )   3,853     (17,192 )
Net income/(loss) $ 21,800   $ 12,153   $ (6,978 ) $ 26,975  
 
2014
Service revenues and sales $ 264,026   $ 96,156   $ -   $ 360,182  
Cost of services provided and goods sold 205,818 51,189 - 257,007
Selling, general and administrative expenses (b) 21,002 25,705 6,942 53,649
Depreciation 4,564 2,561 147 7,272
Amortization   205     137     393     735  
Total costs and expenses   231,589     79,592     7,482     318,663  
Income/(loss) from operations 32,437 16,564 (7,482 ) 41,519
Interest expense (b) (57 ) (111 ) (2,261 ) (2,429 )
Intercompany interest income/(expense) 1,517 680 (2,197 ) -
Other income/(expense)—net   (95 )   198     653     756  
Income/(loss) before income taxes 33,802 17,331 (11,287 ) 39,846
Income taxes (b)   (12,910 )   (6,612 )   4,039     (15,483 )
Net income/(loss) $ 20,892   $ 10,719   $ (7,248 ) $ 24,363  
 

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2015 AND 2014
(in thousands)(unaudited)
               
Chemed
VITAS Roto-Rooter Corporate Consolidated
2015
Service revenues and sales $ 546,073   $ 212,500   $ -   $ 758,573  
Cost of services provided and goods sold 428,274 111,274 - 539,548
Selling, general and administrative expenses (a) 44,207 57,002 15,373 116,582
Depreciation 9,509 6,299 306 16,114
Amortization   338     236     584     1,158  
Total costs and expenses   482,328     174,811     16,263     673,402  
Income/(loss) from operations 63,745 37,689 (16,263 ) 85,171
Interest expense (a) (110 ) (194 ) (1,634 ) (1,938 )
Intercompany interest income/(expense) 3,482 1,642 (5,124 ) -
Other income/(expense)—net   (384 )   35     1,448     1,099  
Income/(loss) before income taxes 66,733 39,172 (21,573 ) 84,332
Income taxes (a)   (25,617 )   (15,011 )   7,808     (32,820 )
Net income/(loss) $ 41,116   $ 24,161   $ (13,765 ) $ 51,512  
 
2014
Service revenues and sales $ 524,438   $ 194,044   $ -   $ 718,482  
Cost of services provided and goods sold 411,210 103,616 - 514,826
Selling, general and administrative expenses (c) 42,716 52,887 13,717 109,320
Depreciation 9,178 4,961 282 14,421
Amortization   624     282     838     1,744  
Total costs and expenses   463,728     161,746     14,837     640,311  
Income/(loss) from operations 60,710 32,298 (14,837 ) 78,171
Interest expense (c) (112 ) (208 ) (5,924 ) (6,244 )
Intercompany interest income/(expense) 2,860 1,330 (4,190 ) -
Other income/(expense)—net   (388 )   139     1,821     1,572  
Income/(loss) before income taxes 63,070 33,559 (23,130 ) 73,499
Income taxes (c)   (24,019 )   (12,808 )   8,265     (28,562 )
Net income/(loss) $ 39,051   $ 20,751   $ (14,865 ) $ 44,937  
 

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARY OF EBITDA
FOR THE THREE MONTHS ENDED JUNE 30, 2015 AND 2014
(in thousands)(unaudited)
               
 
Chemed
VITAS Roto-Rooter Corporate Consolidated
2015
Net income/(loss) $ 21,800 $ 12,153 $ (6,978 ) $ 26,975
Add/(deduct):
Interest expense 53 98 818 969
Income taxes 13,501 7,544 (3,853 ) 17,192
Depreciation 4,724 3,205 153 8,082
Amortization 171     128     283     582  
EBITDA 40,249 23,128 (9,577 ) 53,800
Add/(deduct):
Intercompany interest expense/(income) (1,755 ) (805 ) 2,560 -
Interest income (78 ) (9 ) 1 (86 )
Expenses related to OIG investigation 1,412 - - 1,412
Advertising cost adjustment (c) - (405 ) - (405 )
Acquisition expenses - 131 - 131

Stock option expense

- - 1,343 1,343
Long-term incentive compensation - - 1,457 1,457
Expenses related to securities litigation   -     -     37     37  
Adjusted EBITDA $ 39,828   $ 22,040   $ (4,179 ) $ 57,689  
 
2014
Net income/(loss) $ 20,892 $ 10,719 $ (7,248 ) $ 24,363
Add/(deduct):
Interest expense 57 111 2,261 2,429
Income taxes 12,910 6,612 (4,039 ) 15,483
Depreciation 4,564 2,561 147 7,272
Amortization   205     137     393     735  
EBITDA 38,628 20,140 (8,486 ) 50,282
Add/(deduct):
Intercompany interest expense/(income) (1,517 ) (680 ) 2,197 -
Interest income (43 ) (12 ) (3 ) (58 )
Expenses related to OIG investigation 410 - - 410
Advertising cost adjustment (c) - (399 ) - (399 )
Expenses related to litigation settlements - 32 - 32

Stock option expense

- - 1,144 1,144
Long-term incentive compensation - - 613 613
Expenses related to securities litigation   -     -     189     189  
Adjusted EBITDA $ 37,478   $ 19,081   $ (4,346 ) $ 52,213  
 

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARY OF EBITDA
FOR THE SIX MONTHS ENDED JUNE 30, 2015 AND 2014
(in thousands)(unaudited)
               
 
Chemed
VITAS Roto-Rooter Corporate Consolidated
2015
Net income/(loss) $ 41,116 $ 24,161 $ (13,765 ) $ 51,512
Add/(deduct):
Interest expense 110 194 1,634 1,938
Income taxes 25,617 15,011 (7,808 ) 32,820
Depreciation 9,509 6,299 306 16,114
Amortization   338     236     584     1,158  
EBITDA 76,690 45,901 (19,049 ) 103,542
Add/(deduct):
Intercompany interest expense/(income) (3,482 ) (1,642 ) 5,124 -
Interest income (110 ) (20 ) - (130 )
Expenses related to OIG investigation 2,686 - - 2,686
Acquisition expenses - 131 - 131
Advertising cost adjustment (d) - (911 ) - (911 )
Expenses related to litigation settlements - 5 - 5
Stock option expense - - 2,787 2,787
Long-term incentive compensation - - 2,391 2,391
Expenses related to securities litigation   -     -     37     37  
Adjusted EBITDA $ 75,784   $ 43,464   $ (8,710 ) $ 110,538  
 
2014
Net income/(loss) $ 39,051 $ 20,751 $ (14,865 ) $ 44,937
Add/(deduct):
Interest expense 112 208 5,924 6,244
Income taxes 24,019 12,808 (8,265 ) 28,562
Depreciation 9,178 4,961 282 14,421
Amortization   624     282     838     1,744  
EBITDA 72,984 39,010 (16,086 ) 95,908
Add/(deduct):
Intercompany interest expense/(income) (2,860 ) (1,330 ) 4,190 -
Interest income 20 (19 ) (9 ) (8 )
Expenses related to OIG investigation 1,158 - - 1,158
Expenses related to litigation settlements 113 225 - 338
Acquisition expenses 1 - - 1
Advertising cost adjustment (d) - (1,140 ) - (1,140 )
Stock option expense - - 2,453 2,453
Long-term incentive compensation - - 986 986
Expenses related to securities litigation   -     -     189     189  
Adjusted EBITDA $ 71,416   $ 36,746   $ (8,277 ) $ 99,885  

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
                   
 
 
 
Three Months Ended June 30, Six Months Ended June 30,
2015 2014 2015 2014
Net income as reported $ 26,975 $ 24,363 $ 51,512 $ 44,937
 
Add/(deduct) after-tax cost of:
Stock option expense 849 722 1,759 1,544
Long-term incentive compensation 921 388 1,512 624
Expenses of OIG investigation 868 254 1,658 718
Acquisition expenses 80 - 80 1
Expenses related to securities litigation 23 119 23 119

Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes

- 714 - 2,143
Expenses related to litigation settlements   -   20   3   207
 
Adjusted net income $ 29,716 $ 26,580 $ 56,547 $ 50,293
 
 
Diluted Earnings Per Share As Reported
Net income $ 1.55 $ 1.36 $ 2.96 $ 2.48
Average number of shares outstanding   17,419   17,880   17,419   18,097
 
 
Adjusted Diluted Earnings Per Share
Adjusted net income $ 1.71 $ 1.50 $ 3.25 $ 2.81
Adjusted average number of shares outstanding (e)   17,419   17,759   17,419   17,895
 

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013
(unaudited)
                   
Three Months Ended June 30, Six Months Ended June 30,
OPERATING STATISTICS 2015 2014 2015 2014
Net revenue ($000) (f)
Homecare $ 213,374 $ 200,418 $ 417,915 $ 395,815
Inpatient 25,498 26,032 52,214 52,025
Continuous care   37,588   37,719     75,779   75,894
Total before Medicare cap allowance $ 276,460 $ 264,169 $ 545,908 $ 523,734
Medicare cap allowance   -   (143 )   165   704
Total $ 276,460 $ 264,026   $ 546,073 $ 524,438
Net revenue as a percent of total before Medicare cap allowance
Homecare 77.2 % 75.9 % 76.5 % 75.6 %
Inpatient 9.2 9.8 9.6 9.9
Continuous care   13.6   14.3     13.9   14.5
Total before Medicare cap allowance 100.0 100.0 100.0 100.0
Medicare cap allowance   -   (0.1 )   -   0.1
Total   100.0 %   99.9   %   100.0 %   100.1 %
Average daily census ("ADC") (days)
Homecare 11,285 10,546 11,082 10,511
Nursing home   3,006   2,989     2,964   2,909
Routine homecare 14,291 13,535 14,046 13,420
Inpatient 429 433 434 435
Continuous care   563   568     575   572
Total   15,283   14,536     15,055   14,427
 
Total Admissions 16,683 15,771 33,951 32,124
Total Discharges 15,912 15,673 33,019 31,678
Average length of stay (days) 78.5 82.4 79.1 81.7
Median length of stay (days) 15.0 16.0 14.0 15.0
ADC by major diagnosis
Cerebro 28.6 % 6.3 % 28.4 % 6.4 %
Neurological 23.0 41.2 23.4 40.9
Cancer 16.8 17.3 16.9 17.4
Cardio 17.4 15.7 17.5 15.4
Respiratory 8.0 7.7 7.9 7.8
Other   6.2   11.8     5.9   12.1
Total   100.0 %   100.0   %   100.0 %   100.0 %
Admissions by major diagnosis
Cerebro 18.9 % 7.7 % 18.8 % 7.3 %
Neurological 11.7 21.6 12.3 22.0
Cancer 32.5 33.4 31.5 33.1
Cardio 15.6 15.3 15.7 14.6
Respiratory 10.0 9.6 10.4 9.8
Other   11.3   12.4     11.3   13.2
Total   100.0 %   100.0   %   100.0 %   100.0 %
Direct patient care margins (g)
Routine homecare 52.4 % 53.4 % 52.6 % 53.2 %
Inpatient 6.0 6.9 7.2 5.6
Continuous care 16.7 17.5 16.3 17.0
Homecare margin drivers (dollars per patient day)
Labor costs $ 56.38 $ 53.89 $ 56.79 $ 54.65
Drug costs 6.94 7.26 6.73 7.25
Home medical equipment 6.57 6.76 5.90 6.69
Medical supplies 3.06 3.17 2.99 3.20
Inpatient margin drivers (dollars per patient day)
Labor costs $ 348.40 $ 337.30 $ 343.85 $ 343.50
Continuous care margin drivers (dollars per patient day)
Labor costs $ 589.84 $ 581.00 $ 588.72 $ 587.40
Bad debt expense as a percent of revenues 1.0 % 1.0 % 1.0 % 1.0 %
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 40.8 36.6 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments

31.0

24.4 n.a. n.a.
 

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2015 AND 2014
(unaudited)
                     
 
(a)

Included in the results of operations 2015 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands):

 

Three Months Ended June 30, 2015
VITAS Roto-Rooter Corporate Consolidated
Selling, general and administrative expenses:
Expenses related to OIG investigation $ (1,412 ) $ - $ - $ (1,412 )
Acquisition expenses - (131 ) - (131 )
Stock option expense - - (1,343 ) (1,343 )
Long-term incentive compensation - - (1,457 ) (1,457 )
Expenses related to securities litigation   -     -     (37 )   (37 )
Pretax impact on earnings (1,412 ) (131 ) (2,837 ) (4,380 )
Income tax benefit on the above   544     51     1,044     1,639  
After-tax impact on earnings $ (868 ) $ (80 ) $ (1,793 ) $ (2,741 )
 
Six Months Ended June 30, 2015
VITAS Roto-Rooter Corporate Consolidated
Selling, general and administrative expenses:
Expenses related to OIG investigation $ (2,686 ) $ - $ - $ (2,686 )
Acquisition expenses - (131 ) - (131 )
Expenses related to litigation settlements - (5 ) - (5 )
Stock option expense - - (2,787 ) (2,787 )
Long-term incentive compensation - - (2,391 ) (2,391 )
Expenses related to securities litigation   -     -     (37 )   (37 )
Pretax impact on earnings (2,686 ) (136 ) (5,215 ) (8,037 )
Income tax benefit on the above   1,028     53     1,921     3,002  
After-tax impact on earnings $ (1,658 ) $ (83 ) $ (3,294 ) $ (5,035 )
 
(b)

Included in the results of operations for the three months ended June 30, 2014 are the following significant credits/(charges) which may not be indicative of ongoing operation (in thousands):

 

Three Months Ended June 30, 2014
VITAS Roto-Rooter Corporate Consolidated
Selling, general and administrative expenses:
Expenses related to OIG investigation $ (410 ) $ - $ - $ (410 )
Expenses related to litigation settlements - (32 ) - (32 )
Stock option expense - - (1,144 ) (1,144 )
Long-term incentive compensation - - (613 ) (613 )
Expenses related to securities litigation - - (189 ) (189 )
Interest expense:

 

Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes

  -     -     (1,130 )   (1,130 )
Pretax impact on earnings (410 ) (32 ) (3,076 ) (3,518 )
Income tax benefit on the above   156     12     1,133     1,301  
After-tax impact on earnings $ (254 ) $ (20 ) $ (1,943 ) $ (2,217 )

 

(c)

Included in the results of operations for the six months ended June 30, 2014 are the following significant credits/(charges) which may not be indicative of ongoing (in thousands):

 

Six Months Ended June 30, 2014
VITAS Roto-Rooter Corporate Consolidated
Selling, general and administrative expenses:
Expenses related to OIG investigation $ (1,158 ) $ - $ - $ (1,158 )
Expenses related to litigation settlements (113 ) (225 ) - (338 )
Acquisition expenses (1 ) - - (1 )
Stock option expense - - (2,453 ) (2,453 )
Long-term incentive compensation - - (986 ) (986 )
Expenses related to securities litigation - - (189 ) (189 )
Interest expense:

Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes

  -     -     (3,389 )   (3,389 )
Pretax impact on earnings (1,272 ) (225 ) (7,017 ) (8,514 )
Income tax benefit on the above   483     88     2,587     3,158  
After-tax impact on earnings $ (789 ) $ (137 ) $ (4,430 ) $ (5,356 )
 
(d)  

Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the second quarters of 2015 and 2014, GAAP advertising expense for Roto-Rooter totaled $6,391,000 and $6,087,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the second quarters of 2015 and 2014 would total $6,796,000 and $6,486,000, respectively.

 

Similarly, for the first six months of 2015 and 2014, GAAP advertising expense for Roto-Rooter totaled $12,458,000 and $12,602,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the first six months of 2015 and 2014 would total $13,369,000 and $13,742,000, respectively

 
(e)

Adjusted diluted average shares outstanding excludes the estimated dilutive impact of the convertible notes prior to conversion of these notes on May 15, 2014 (121,000 shares for the three months ended June 30, 2014 and 202,000 shares for the six months ended June 30, 2014) as this impact was entirely offset upon the exercise of the note hedges on May 15, 2014.

 
(f)

VITAS has 10 large (greater than 450 ADC), 17 medium (greater than 200 but less than 450 ADC) and 20 small (less than 200 ADC) hospice programs. Of VITAS' 34 unique Medicare provider numbers, 32 provider numbers have a Medicare cap cushion of 10% or greater during the first nine months of the current cap year; one provider number has a Medicare cap cushion between 5% and 10%; and one provider number has a cap cushion between 0% and 5%.

 
(g) Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation.

CONTACT:
Chemed Corporation
David P. Williams, 513-762-6901